• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up2.00% Nasdaq Up1.66%

    Relypsa, Inc. (RLYP)

    -NasdaqGS
    17.48 Up 0.27(1.57%) Feb 12, 4:00PM EST
    |After Hours : 17.52 Up 0.04 (0.23%) Feb 12, 7:59PM EST
    ProfileGet Profile for:
    Relypsa, Inc.
    100 Cardinal Way
    Redwood City, CA 94063
    United States - Map
    Phone: 650-421-9500
    Website: http://www.relypsa.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:241

    Business Summary 

    Relypsa, Inc., a biopharmaceutical company, focuses on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular, and metabolic diseases in the United States. Its lead product candidate includes Patiromer, a non-absorbed potassium binding polymer that completed Phase III clinical trial for the treatment of hyperkalemia. The company was founded in 2007 and is based in Redwood City, California.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Relypsa, Inc.

    Corporate Governance 
    Relypsa, Inc.’s ISS Governance QuickScore as of Feb 1, 2016 is 8. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 8; Compensation: 6.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. John A. Orwin , 51
    Chief Exec. Officer, Pres and Director
    787.00K0.00
    Ms. Mary E. Corbett , 64
    Sr. VP of HR
    337.00K0.00
    Mr. J. Scott Garland , 47
    Chief Commercial Officer and Sr. VP
    170.00K0.00
    Ms. Kristine M. Ball , 44
    Chief Financial Officer, Principal Accounting Officer and Sr. VP
    N/AN/A
    Dr. Wilhelm Stahl Ph.D., 56
    Chief Technology Officer and Sr. VP
    N/AN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders